Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology

Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.

RTTNews | 615天前

Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY

Vertex Pharmaceuticals Inc. (VRTX) announced Friday that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

RTTNews | 723天前

CRISPR Therapeutics Says FDA Grants RMAT Designation To CTX130

Biopharmaceutical company CRISPR Therapeutics (CRSP) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the Company's wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS).

RTTNews | 1166天前

Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that the company has entered into a definitive agreement under which Vertex will acquire privately-held biotechnology company ViaCyte for $320 million in cash.

RTTNews | 1245天前

Vertex Pharma Says FDA Lifts Clinical Hold On Phase 1/2 Trial Of VX-880 To Treat Type 1 Diabetes

Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia.

RTTNews | 1251天前

Thai Bourse Expected To Snap Losing Streak On Monday

Ahead of Friday's holiday for King Bhumibol's birthday, the Thai stock market had ticked lower in back-to-back sessions, easing almost 4 points or 0.3 percent along the way. The Stock Exchange of Thailand now sits just beneath the 1,275-point plateau although it may stop the bleeding on Monday.

RTTNews | 1小時18分鐘前

Slight Upside Tipped For Indonesia Stock Market

The Indonesia stock market has moved lower in two of three trading days since the end of the two-day winning streak in which it had picked up almost 110 points or 1.3 percent. The Jakarta Composite Index now sits just above the 8,630-point plateau and it figures to remain rangebound again on Monday.

RTTNews | 1小時48分鐘前

Japanese Market Slightly Lower

The Japanese stock market is trading slightly lower on Monday, extending the losses in the previous session, despite the broadly positive cues from Wall Street on Friday, with the Nikkei 225 falling below the 50,450 level, with weakness is index heavyweights, financial and technology stocks partially offset by gains in automakers and exporter stocks.

RTTNews | 1小時49分鐘前

EURUSD	1.16514	GBPUSD	1.33378	AUDUSD	0.66448
USDJPY	155.03	USDCAD	1.38227	USDCHF	0.80353